[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530550":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Hanlim Pharm. Co., Ltd.","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Seokgi Yoon","CHEONAN ENDO MEDICAL CLINIC","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Yeonhwa Kim","CONTACT","82-2-3489-6163","yh@hanlim.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":7,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Cheonan Endo Medical Clinic","RECRUITING","Cheonan","South Korea",{"type":26,"coordinates":27},"Point",[28,29],127.1522,36.8065,{"lat":29,"lon":28},[32],{"name":10,"role":16,"phone":33,"phoneExt":7,"email":7},"82-41-592-7201",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100530550","the-prescription-patterns-and-clinical-efficacy-of-tenero-tabtenero-m-sr-tab-100530550",false,"NCT06188234","The Prescription Patterns and Clinical Efficacy of Tenero Tab\u002FTenero M SR Tab","Observational Study on the Prescription Patterns and Clinical Efficacy of Tenero Tab\u002FTenero M SR Tab in Korean Type 2 Diabetes Mellitus Patients","Inclusion Criteria:\n\n1. Adults over 19 years of age\n2. Individuals diagnosed with type 2 diabetes.\n3. Individuals who, at the clinical discretion, are prescribed Tenero Tab or Tenero M SR Tab for the purpose of diabetes treatment for the first time.\n4. Individuals who have voluntarily provided written consent to participate in this study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Individuals who are contraindicated according to the approved indications of Tenero Tab\u002FTenero M SR Tab.\n3. Other cases where the principal investigator and study personnel deem individuals ineligible for participation in this clinical trial.","ALL","19 Years",{"count":46,"type":47},3000,"ESTIMATED","OBSERVATIONAL","This study is to observe the prescription patterns and clinical efficacy of patients prescribed with Tenero Tab\u002FTenero M SR Tab for diabetes treatment in routine clinical practice.",[51],"Diabetes Mellitus, Type 2",[53,54],"Metformin HCI","Teneligliptin hydrochloride","2024-02-13",{"date":57,"type":58},"2024-02-15","ACTUAL",{"date":60,"type":58},"2022-12-27",{"date":62,"type":47},"2026-06",{"name":5,"class":6},1]